About Kardion
Kardion is a cardiovascular medical device company developing next-generation mechanical circulatory support technology, with dual headquarters in Irvine, California and Stuttgart, Germany. Every moment matters. Our team is building toward a future where circulatory support gives patients and clinicians more time, more options, and more certainty.

Position Summary
The Director, Global Information Technology defines and executes Kardion's enterprise technology strategy across our United States and German operations. This leader will unify and lead the global IT organization, serve as the primary technology advisor to executive leadership, and ensure technology investments are directed toward the areas of greatest value to the business.
The role requires both strategic influence and technical depth. The Director will define a multi-year information technology roadmap, report on performance, risk, and investment to executive leadership, and remain close enough to the technology to guide architecture decisions and lead the team through execution. Building on a foundation established by our teams in Irvine and Stuttgart and our external partners, the Director will bring both sites together under a common global operating model and continue to mature the capabilities expected of a regulated, multinational medical device company.

What You'll Do
Strategy and Leadership

Define and own Kardion's global IT strategy, roadmap, and budget, and serve as the primary technology advisor to the CEO and executive leadership team.
Establish a single global operating model across Irvine and Stuttgart, including standards, service levels, and a sustainable balance of internal capability and specialized external expertise.
Build, lead, and develop the global IT organization, and report on performance, risk, and investment to executive leadership.

Enterprise Applications and Data

Own the enterprise application portfolio and integration architecture, partnering with functional leaders to translate business requirements into system capability and maintain a coherent landscape as the company grows.
Provide leadership and direction to the ERP function, ensuring the program supports manufacturing, quality, supply chain, and finance at commercial scale.
Strengthen data management, reporting, and analytics so leadership has reliable visibility across the business.
Develop and own an AI governance framework covering approved tools, data protection, intellectual property, and responsible use.

Regulated Systems and Audit Readiness

Own computer system validation for regulated systems in partnership with Quality Assurance.
Ensure IT processes, controls, and documentation satisfy FDA and ISO 13485 requirements, including electronic records, access control, change control, and records retention.
Serve as the IT subject matter expert during regulatory inspections, notified body audits, and internal audits.

Cybersecurity, Privacy, and Risk

Own the enterprise information security program, aligned to a recognized framework and delivered through a combination of internal resources and trusted partners.
Own incident response, third-party risk management, and the IT controls that protect the integrity of business and financial systems.
Ensure compliance with global data privacy requirements, including GDPR and applicable US state law, in partnership with Legal and HR.

Infrastructure and Workplace Technology

Own global infrastructure architecture including cloud, identity, network, endpoint, and collaboration platforms across both sites.
Ensure reliable, secure, and audit-ready technology support for laboratory, engineering, and manufacturing environments.
Establish business continuity and disaster recovery capability, and set standards for employee onboarding and offboarding, support responsiveness, and asset management.

Facilities

Oversight of the Irvine facility and physical security and access.

What We're Looking For
Required

10 or more years of progressive information technology experience, including 4 or more years leading teams and owning an IT function or major domain.
Direct experience leading or heavily contributing to an ERP implementation, migration, or major upgrade.
Proven track record building and scaling IT capability in a growing organization, across both internal teams and external partners.
Working knowledge of modern cloud, identity, and endpoint platforms sufficient to guide architecture decisions and evaluate vendor proposals.
Accountability for an information security program, whether delivered internally, through partners, or a combination.
Experience supporting multi-site operations, including at least one international site, with the ability to communicate complex technical and risk topics clearly to executives, auditors, and non-technical business partners.
Bachelor's degree in information technology, computer science, engineering, or equivalent practical experience.

Preferred

Medical device, pharmaceutical, biotech, or diagnostics experience strongly preferred.
Depth in one or more specialist areas within the scope of this role, such as information security, infrastructure, enterprise applications, or validation.
Relevant certifications such as CISSP, CISM, ITIL, or PMP.

Physical Demands and Work Environment

Frequent use of a computer keyboard, monitor, and mouse; frequent sitting, standing, and walking; occasional lifting or moving of objects of various weights.
Irvine, California based. This is a fully onsite position, with periodic international travel to Stuttgart, Germany.
Fast-paced environment with shifting priorities and multiple concurrent projects, including occasional work outside standard business hours to support global colleagues and critical deployments.

Compensation
The anticipated base salary range for this position is $200,00-230,000 annually. Actual compensation will be determined based on experience, qualifications, skills, and location. Kardion offers a comprehensive benefits package including medical, dental, and vision coverage, 401(k), and paid time off.

Equal Opportunity Statement
Kardion is an equal opportunity employer. We are committed to creating an inclusive environment for all employees and do not discriminate on the basis of race, color, religion, sex, sexual orientation, gender identity, national origin, age, disability, veteran status, or any other protected characteristic under applicable law.

About the company

Kardion is a medical technology company developing a catheter-based heart-support system. The company researches, engineers, tests, and prepares clinical and manufacturing programs for an implantable cardiovascular device. It serves clinicians, patients, researchers, regulators, clinical partners, and medical-device suppliers. Its operating model centers on device development coordinated across engineering, clinical, quality, regulatory, and manufacturing teams. Teams work across biomedical engineering, clinical affairs, quality, regulatory, manufacturing, research, and operations. Its work connects cardiovascular medical devices expertise with coordinated delivery for clinical and healthcare stakeholders.

Company Size

N/A

Company Stage

N/A

Total Funding

N/A

Headquarters

N/A

Founded

N/A

Simplify's Take

What believers are saying

PICANTE enrolled in 2026 across Hartford and Christ Hospital, proving active clinical execution.
September 2026 trial pages describe an enrolling pivotal study, not a stalled prototype.
Patents published in March and August 2026 strengthen bargaining power with partners and acquirers.

What critics are saying

PICANTE results are due December 31, 2026; a miss blocks FDA and hospital adoption.
Kardion shows no disclosed funding, limiting manufacturing scale and trial expansion.
Impella’s incumbent network at Abiomed and Johnson & Johnson crushes weak clinical superiority claims.

What makes Kardion unique

Kardion’s CORY P4 targets high-risk PCI with randomized head-to-head evidence against Impella CP.
The company owns implantable vascular support patents filed in 2026, including flow-monitoring designs.
Steve Williamson became CEO in August 2026, signaling a commercialization-focused MedTech team.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
Dental Insurance
Vision Insurance

Company News

PR Newswire

Sep 22nd, 2026

Cadence Neuroscience appoints medtech executive Chris Cronin as CEO to lead clinical execution and platform growth.

Cadence Neuroscience appoints medtech executive Chris Cronin as CEO to lead clinical execution and platform growth. Cadence Neuroscience Sep 22, 2026, 09:00 ET Veteran medtech executive brings leadership experience across neuromodulation, clinical-stage company building, and commercialization; Founder Kent Leyde to lead technology and product development as CTO REDMOND, Wash., Sept. 22, 2026 /PRNewswire-PRWeb/ - Cadence Neuroscience, a clinical-stage company developing a biomarker-guided platform for personalized neuromodulation, announced the appointment of medtech executive Chris Cronin as Chief Executive Officer. Cronin joins as Cadence prepares for clinical evaluation of its investigational Biomarker Targeted Stimulation (BTS) system in focal drug-resistant epilepsy as its first indication, while building the capabilities to develop the platform across additional neurological conditions. Cronin brings nearly three decades of experience across medical technology, healthcare, finance, business development, and commercialization, including leadership experience in neuromodulation and other complex therapeutic-device categories. Kent Leyde, company founder, will become Chief Technology Officer and continue to lead Cadence's technology development, product strategy, and key external collaborations. Cronin most recently served as CEO and President of KARDION, a cardiovascular medical technology company, where he led the organization through a critical stage of growth as it moved from first-in-human to pivotal study. Previously, he held executive leadership roles at MOBĒ, helping scale the early-stage healthcare company, and spent more than a decade at Medtronic in leadership roles spanning cardiac and restorative therapies. As a Business Director at Medtronic, he held P&L responsibility across eight countries and regions for one of the company's largest franchises, with experience spanning neuromodulation modalities including deep brain stimulation, spinal cord stimulation, and intrathecal baclofen. Cadence's investigational BTS system is designed to use patient-specific neural biomarkers to inform stimulation and measure the brain's response to therapy. This biomarker-guided approach is intended to provide clinicians and researchers with real-time physiological feedback that may support more personalized and adaptable neuromodulation. Cadence is initially evaluating BTS in focal drug-resistant epilepsy, a serious condition in which many patients continue to experience seizures despite available anti-seizure medications and may have limited treatment options. This substantial unmet need makes focal drug-resistant epilepsy an important first indication for clinical evaluation of Cadence's platform. "Cadence has developed a fundamentally different approach to personalized neuromodulation - using patient-specific biomarkers not only to guide stimulation, but to measure how the brain responds," said Cronin. "The company has built a compelling technical and scientific foundation, and I'm excited to work with Kent, the board, clinical collaborators, and the broader team at this pivotal stage as we prepare for an important clinical study in focal drug-resistant epilepsy and build toward the broader potential of the Cadence platform across neurological conditions." "Chris' patient-centered approach to healthcare and medical devices is closely aligned with the way we've built Cadence from the beginning," said Leyde. "He brings deep business and medtech leadership experience at an important point in our growth. I'm pleased to have Chris leading the company while I focus on developing the technology and products at the heart of our work." "Cadence has reached an important inflection point," said Dan Moore, Independent Board Director at Cadence Neuroscience. "The company combines innovative technology with a clear initial clinical focus. Chris's experience in complex therapeutic-device categories and growth-stage medtech leadership complements Kent's continued technical leadership, positioning Cadence to execute its clinical plan and build toward future commercialization." Cadence's technology originated from research conducted by a Mayo Clinic Neurology and Neurosurgery team led by Gregory Worrell, M.D., Ph.D., a Mayo Clinic epileptologist and lead investigator. Cadence is building on this scientific foundation as it advances the BTS system through clinical evaluation. About Cadence Neuroscience Cadence Neuroscience is a clinical-stage medical technology company developing a biomarker-guided platform for personalized neuromodulation. Its investigational Biomarker Targeted Stimulation (BTS) system is designed to use patient-specific neural biomarkers to inform stimulation and measure the brain's response to therapy in real time. Cadence is initially advancing BTS in focal drug-resistant epilepsy, with a long-term goal of developing the platform for additional neurological conditions. Founded in 2017 and headquartered in Redmond, Washington, Cadence is building on technology originating from Mayo Clinic research. Cadence is backed by leading healthcare and technology investors, including F-Prime Capital, Jazz Venture Partners, LivaNova, Angelini Lumira Biosciences Fund, and Mayo Clinic. For more information, visit cadenceneuro.com. Mayo Clinic and Dr. Worrell have a financial interest in the technology referenced in this news release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education, and research. Cadence Neuroscience is developing investigational medical technologies that have not been approved or cleared by the U.S. Food and Drug Administration (FDA) or other health authorities. Any forward-looking statements reflect current expectations and are subject to risks and uncertainties. Actual results may differ materially. This information is for educational purposes only and does not constitute medical advice or investigational device promotion. Patients should consult qualified healthcare providers regarding diagnosis and treatment options. Currently, these investigational technologies are only accessible through participation in a clinical trial. To learn more about these investigational technologies and how to access them, talk with your qualified healthcare provider or visit www.clinicaltrials.gov. Media Contact Alysa Wood, Cadence Neuroscience, 1 (425) 298-3184, [email protected], https://cadenceneuro.com/ SOURCE Cadence Neuroscience

Kardion

Global Information Technology Director

About the job